Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pharma Q3 Results Preview: Biogen, Gilead, Celgene

Executive Summary

Ozanimod re-filing is a big near-term catalyst for Celgene. Biogen investors will be looking for more information about the development and regulatory strategy for BAN2401 in Alzheimer's. And Gilead investors want reassurance that the company will return to growth soon. 

Advertisement

Related Content

Humira Under Pressure As NHS England Invites 'Competitive Prices' For Biosimilars
Celgene’s Positive Phase III Data For Otezla In Scalp Psoriasis Could Yield Broader Label
"Impressive" HbA1c And Weight Reductions Spur Phase III Plans For Lilly's Dual Incretin Agonist
Gilead’s HCV Authorized Generics Effort Will Draw Market Share From AbbVie
Multiple Myeloma: A Growth Market Set To Shrink As Revlimid Generics Hit
Celgene Maintains Otezla Confidence, But Is Reconsidering IBD Indications
Biogen, Eisai Report BAN2401 Seemingly Positive In Alzheimer's; Others Skeptical
New Data Cast Doubt On Gilead's Phase III NASH Candidate Selonsertib
More Bad News: Celgene Reveals Refuse-To-File Letter For Ozanimod In MS
Gilead's Biktarvy Approval Heightens HIV Competition With ViiV

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC123990

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel